Anti-TNF-α therapy in the management of severe neurosarcoidosis: A report of five cases from a single centre and literature review

Clinical and Experimental Rheumatology

Volumn 32, Issue 2, 2014, Pages 275-284

  Riancho Zarrabeitia, Leyre ^a   Delgado Alvarado, Manuel ^a,b   Riancho, Javier ^a   Oterino, Agustín ^a   Sedano, Maria J ^a   Rueda Gotor, Javier ^a   Pérez Martín, Inés ^a   González Vela, María C ^a   Berciano, José ^a   González Gay, Miguel A ^a   Blanco, Ricardo ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

Author keywords

Anti TNF therapy; Central nervous system; Neurosarcoidosis

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGED; ARACHNOIDITIS; BRAIN ISCHEMIA; CAUDA EQUINA SYNDROME; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; INFECTION; LOW BACK PAIN; LYMPH NODE BIOPSY; MALE; MEDIASTINOSCOPY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESIS; PATIENT COMPLIANCE; PNEUMOCYSTIS PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELAPSE; REVIEW; SARCOIDOSIS; CEREBROSPINAL FLUID ANALYSIS; DOSE RESPONSE; GAIT DISORDER; NEUROLOGIC EXAMINATION; PHYSICAL EXAMINATION; PNEUMONIA;

ADRENAL CORTEX HORMONES; ADULT; AGED; BIOPSY; CENTRAL NERVOUS SYSTEM DISEASES; DRUG RESISTANCE; FEMALE; GRANULOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPH NODES; MALE; MIDDLE AGED; RECURRENCE; SARCOIDOSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904729719     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. HAMZEH N: Sarcoidosis. Med Clin North Am 2011; 95: 1223-34.
2. CULVER DA: Sarcoidosis. Immunol Allergy Clin North Am 2012; 32: 487-511.
3. LACOMIS D: Neurosarcoidosis. Curr Neuropharmacol 2011; 9: 429-36.
4. PETURSDOTTIR D, HARALDSDOTTIR SO, BJARNADOTTIR K et al.: Sarcoid arthropathy and the association with the human leukocyte antigen. The Icelandic Sarcoidosis Study. Clin Exp Rheumatol 2013; 31: 711-6.
5. IANNUZZI MC, RYBICKI BA, TEIRSTEIN AS: Sarcoidosis. N Engl J Med 2007; 357: 2153-65.
6. BAUGHMAN RP, COSTABEL U, du BOIS RM: Treatment of sarcoidosis. Clin Chest Med 2008; 29: 533-x.
7. PEREIRA J, ANDERSON NE, McAULEY D, BERGIN P, KILFOYLE D, FINK J: Medically refractory neurosarcoidosis treated with infliximab. Intern Med J 2011; 41: 354-7.
8. COTTIN V: Update on bioagent therapy in sarcoidosis. F1000 Med Rep 2010; 2.
9. JUDSON MA, BAUGHMAN RP, COSTABEL U et al.: Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31: 1189-96.
10. TOTH C, MARTIN L, MORRISH W, COUTTS S, PARNEY I: Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab. Acta Neurol Scand 2007; 116: 259-62.
11. DOTY JD, MAZUR JE, JUDSON MA: Treatment of sarcoidosis with infliximab. Chest 2005; 127: 1064-71.
12. MORAVAN M, SEGAL BM: Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 2009; 72: 337-40.
13. KOBYLECKI C, SHAUNAK S: Refractory neurosarcoidosis responsive to infliximab. Pract Neurol 2007; 7: 112-5.
14. SANTOS E, SHAUNAK S, RENOWDEN S, SCOLDING NJ: Treatment of refractory neurosarcoidosis with Infliximab. J Neurol Neurosurg Psychiatry 2010; 81: 241-6.
15. SODHI M, PEARSON K, WHITE ES, CULVER DA: Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med 2009; 103: 268-73.
16. PETTERSEN JA, ZOCHODNE DW, BELL RB, MARTIN L, HILL MD: Refractory neurosarcoidosis responding to infliximab. Neurology 2002; 59: 1660-1.
17. KUMAR G, KANG CA, GIANNINI C: Neurosarcoidosis presenting as a cerebellar mass. J Gen Intern Med 2007; 22: 1373-6.
18. CARTER JD, VALERIANO J, VASEY FB, BOGNAR B: Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 2004; 117: 277-9.
19. WONG M, ZIRING D, KORIN Y et al.: TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008; 126: 121-36.
20. ZAJICEK JP, SCOLDING NJ, FOSTER O et al.: Central nervous system sarcoidosis--diagnosis and management. QJM 1999; 92: 103-17.
21. LAZARUS A: Sarcoidosis: epidemiology, etiology, pathogenesis, and genetics. Dis Mon 2009; 55: 649-60.
22. RUSSELL E, LUK F, MANOCHA S, HO T, O'CONNOR C, HUSSAIN H: Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. Semin Arthritis Rheum 2013.
23. HOSTETTLER KE, STUDLER U, TAMM M, BRUTSCHE MH: Long-term treatment with infliximab in patients with sarcoidosis. Respiration 2012; 83: 218-24.
24. NOWAK DA, WIDENKA DC: Neurosarcoidosis: a review of its intracranial manifestation. J Neurol 2001; 248: 363-72.
25. VARGAS DL, STERN BJ: Neurosarcoidosis: diagnosis and management. Semin Respir Crit Care Med 2010; 31: 419-27.
26. CHAPELON C, ZIZA JM, PIETTE JC et al.: Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore) 1990; 69: 261-76.
27. HOLMES J, LAZARUS A: Sarcoidosis: extrathoracic manifestations. Dis Mon 2009; 55: 675-92.
28. KHOURY J, WELLIK KE, DEMAERSCHALK BM, WINGERCHUK DM: Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of central nervous system sarcoidosis. Neurologist 2009; 15: 108-11.
29. SPIEGEL DR, MORRIS K, RAYAMAJHI U: Neurosarcoidosis and the complexity in its differential diagnoses: a review. Innov Clin Neurosci 2012; 9: 10-6.
30. BIHAN H, CHRISTOZOVA V, DUMAS JL et al.: Sarcoidosis: clinical, hormonal, and magnetic resonance imaging (MRI) manifestations of hypothalamic-pituitary disease in 9 patients and review of the literature. Medicine (Baltimore) 2007; 86: 259-68.
31. YOUNGER DS, HAYS AP, BRUST JC, ROWLAND LP: Granulomatous angiitis of the brain. An inflammatory reaction of diverse etiology. Arch Neurol 1988; 45: 514-8.
32. SOHN M, CULVER DA, JUDSON MA, SCOTT TF, TAVEE J, NOZAKI K: Spinal Cord Neurosarcoidosis. Am J Med Sci 2013.
33. HOITSMA E, FABER CG, SANTEN-HOEUFFT M, DE VRIES J, REULEN JP, DRENT M: Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 73-7.
34. TORRALBA KD, QUISMORIO FP, Jr.: Sarcoidosis and the rheumatologist. Curr Opin Rheumatol 2009; 21: 62-70.
35. DUTRA LA, BRAGA-NETO P, OLIVEIRA RA, PEDROSO JL, ABRAHAO A, BARSOTTINI OG: Neurosarcoidosis: guidance for the general neurologist. Arq Neuropsiquiatr 2012; 70: 293-9.
36. BAUGHMAN RP, LOWER EE, BRADLEY DA, RAYMOND LA, KAUFMAN A: Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005; 128: 1062-47.
37. UTZ JP, LIMPER AH, KALRA S et al.: Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124: 177-85.
38. CROFT AP, SITUNAYAKE D, KHAIR O et al.: Refractory multisystem sarcoidosis responding to infliximab therapy. Clin Rheumatol 2012; 31: 1013-8.
39. PANSELINAS E, RODGERS JK, JUDSON MA: Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology 2009; 14: 522-8.
40. MARNANE M, LYNCH T, SCOTT J, STACK J, KELLY PJ: Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab. J Neurol 2009; 256: 139-40.
41. LAHMER T, KNOPF A, LANZL I, HEEMANN U, THUERMEL K: Using TNF-alpha antagonist adalimumab for treatment for multisystem sarcoidosis: a case study. Rheumatol Int 2012; 32: 2367-70.
42. HEFFERNAN MP, SMITH DI: Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 2006; 142: 17-9.
43. PARISER RJ, PAUL J, HIRANO S, TOROSKY C, SMITH M: A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2012.
44. FIELD S, REGAN AO, SHEAHAN K, COLLINS P: Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol 2010; 35: 795-6.
45. CALABRESE LH: Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003; 21: 241-8.
46. BONGARTZ T, SUTTON AJ, SWEETING MJ, BUCHAN I, MATTESON EL, MONTORI V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and metaanalysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
47. TONG D, MANOLIOS N, HOWE G, SPENCER D: New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Intern Med J 2012; 42: 89-94.
48. MAO-DRAAYER Y, CASH T: Neurosarcoidosis in a patient treated with tumor necrosis factor alpha inhibitors. J Neurol 2013; 260:651-3.
49. GONZALEZ-LOPEZ MA, BLANCO R, GONZALEZ-VELA MC, FERNANDEZ-LLACA H, RODRIGUEZ-VALVERDE V: Development of sarcoidosis during etanercept therapy. Arthritis Rheum 2006; 55: 817-20.
50. SALVATIERRA J, MAGRO-CHECA C, ROSALES-ALEXANDER JL, RAYA-ALVAREZ E: Acute sarcoidosis as parotid fever in rheumatoid arthritis under anti-tumor necrosis factoralpha therapy. Rheumatology (Oxford) 2011; 50: 1346-8.
51. STURFELT G, CHRISTENSSON B, BYNKE G, SAXNE T: Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab. J Rheumatol 2007; 34: 2313-4.
52. BEJERANO C, BLANCO R, GONZALEZ-VELA C, AGUERO R, CARRIL JM, GONZALEZ-GAY MA: Refractory polymyalgia rheumatica as presenting manifestation of large-vessel vasculitis associated to sarcoidosis. Successful response to adalimumab. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S94-S97.
53. KATZ JM, BRUNO MK, WINTERKORN JM, NEALON N: The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch Neurol 2003; 60: 426-30.
54. SOLLBERGER M, FLURI F, BAUMANN T et al.: Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol 2004; 251: 760-1.
55. SALAMA B, GICQUEL JJ, LENOBLE P, DIGHIERO PL: Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist. Can J Ophthalmol 2006; 41: 766-8.
56. DOLHUN R, SRIRAM S: Neurosarcoidosis presenting as longitudinally extensive transverse myelitis. J Clin Neurosci 2009; 16: 595-7.
57. CHINTAMANENI S, PATEL AM, PEGRAM SB, PATEL H, ROPPELT H: Dramatic response to infliximab in refractory neurosarcoidosis. Ann Indian Acad Neurol 2010; 13: 207-10.